| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Issues Approvable Letter for Bonefos (Clodronate) for Adjuvant Treatment of Breast Cancer BERLIN, GERMANY -- January 7, 2005 -- Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Bonefos® (clodronate), an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. Berlex, Inc., Schering's U.S. affiliate, plans to request a meeting with the FDA to discuss the information that is needed to obtain approval, and will submit this information as quickly as possible. "We look forward to the opportunity to meet with the FDA so we can advance the approval process," said Marc Rubin, MD, member of the Schering AG Board of Executive Directors responsible for Development and Oncology. This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
SOURCE: Schering AG
|